Bivalent Human Papilloma Virus Vaccine (Cervarix) in the treatment of cutaneous warts | ||||
| Zagazig University Medical Journal | ||||
| Article 35, Volume 30, Issue 2, March and April 2024, Page 570-575 PDF (910.91 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2021.91611.2321 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Samia Ali Ibrahim1; Shima Maher Hamed  2; howyda Mohamed Ibrahim3; Hala Mohamed Morsi 4
| ||||
| 1Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| 2zagazig general Hospital | ||||
| 3Zagazig University Hospital | ||||
| 4dermatology &venereology department, faculty of medicine, Zagazig university | ||||
| Abstract | ||||
| Abstract Background Bivalent human papilloma virus (HPV) vaccine has a successful effect in therapy of recalcitrant cutaneous warts. Objective The purpose of this study is to assess the efficacy and safety of intralesional (IL) injection of bivalent HPV vaccine (cervarix) versus IL saline in therapy of recalcitrant cutaneous warts. Patients and Methods Forty-four patients with resistant warts to therapy were classified into 2 groups; 22 patients in each group. Group A was received Cervarix vaccine 0.1ml into the biggest wart 2-weeks apart and group B (control) was received IL saline. The patients in both groups received sessions until the patients achieved complete clearance or for a five sessions. Results One month after the treatment, 86.4% of patients achieved complete response in group A (IL cervarix vaccine) versus to 4.2 % of the control (group B) with a highly significant difference (P | ||||
| Keywords | ||||
| Cervarix (Bivalent) HPV vaccine; Intralesional therapy; Recalcitrant cutaneous warts | ||||
|
Statistics Article View: 466 PDF Download: 126 |
||||
